Skip to main content
OpenTrials
Completed

NCT Number: NCT02414412

Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults

This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults. 58 subjects received 500 mg of Ulmus macrocarpa water extract per day or a placebo for 4 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subject has peripheral white blood cells between 4,000/Ul and 8,000/Ul

Exclusion criteria

  • History of renal disease
  • History of diabetes mellitus
  • History of immune disease

Treatment and study plan

Ulmus macrocarpa water extract

Dietary Supplement

Primary outcomes

  1. serum natural killer cell activity

    Time frame: 1 month

Secondary outcomes

  1. peripheral white blood cell

    Time frame: 1 month

  2. serum tumor necrosis factor-alpha level

    Time frame: 1 month

  3. serum interferon-gamma

    Time frame: 1 month

  4. serum interleukins(1betta, 2,4,8,10, and 12)

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Pusan National University Hospital

Other

Collaborators

  • Bio Port Korea Inc.

Registry information

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Apr 10, 2015
Registry last updated
Nov 3, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.